Among newly launched drugs, Enhertu, an oncology drug marketed by AstraZeneca, emerged as the highest-selling new product in 2024, generating sales of nearly Rs 58 crore in its first year. The high sales highlight both the drug’s adoption and the rising incidence of cancer in India, a TOI report stated. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/gsks-antibiotic-drug-augmentin-is-indias-highest-selling-brand-with-rs-80-crore-monthly-sale/118325626